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ABSTRACT 36 
Objectives: Data are limited on clinical presentation and outcomes in elderly patients 37 
with acute symptomatic isolated subsegmental pulmonary embolism (SSPE). We 38 
compared clinical presentation, risk factors, processes of care, and outcomes between 39 
elderly patients with SSPE and patients with more proximal pulmonary embolism (PE). 40 
Methods: We prospectively followed 578 patients aged ≥65 years with acute 41 
symptomatic isolated SSPE or proximal PE in a multicentre Swiss cohort study. We 42 
compared quality of life at three months using the PEmb-QoL, and examined the 43 
independent association between localization of PE and clinical outcomes (recurrent 44 
venous thromboembolism [VTE], overall mortality) using regression models with 45 
adjustment for potential confounders. 46 
Results: Overall, 11% of patients had isolated SSPE. Patients with SSPE were less 47 
likely to have a pulse ≥110/min (3% vs. 13%), but more likely to have active cancer 48 
(28% vs. 15%) and to receive outpatient care (11% vs. 4%) than patients with proximal 49 
PE. Virtually all patients (98%) with SSPE received anticoagulants. Quality of life did 50 
not differ between the groups at 3 months. No patient with SSPE vs. seven patients 51 
with proximal PE died from the index PE event. No significant difference was observed 52 
for the 3-year cumulative incidence of recurrent VTE (7% vs. 12%) and death (29% vs. 53 
20%). After adjustment, SSPE was not associated with a lower risk of clinical outcomes 54 
than proximal PE. 55 
Conclusions: Clinical presentation and incidences of adverse outcomes did not differ 56 
significantly between elderly patients with SSPE or proximal PE, although the power 57 
to detect differences might have been limited given the small number of events. Thus, 58 
our study does not provide evidence that unselected, elderly patients with SSPE have 59 
a more benign clinical course.  60 
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 63 
Abbreviations: 64 
AC Anticoagulation  65 
BP Blood pressure 66 
CI Confidence interval 67 
CT(PA) Computed tomography (pulmonary angiography) 68 
DOAC Direct oral anticoagulant 69 
DVT Deep vein thrombosis 70 
Hs-cTNT High-sensitivity cardiac troponin T 71 
INR International Normalized Ratio 72 
IQR Interquartile range 73 
NSAID Non-steroidal anti-inflammatory drugs 74 
PEmb-QoL Pulmonary Embolism Quality of Life 75 
PESI Pulmonary Embolism Severity Index 76 
(S)HR (Sub-)hazard ratios 77 
(SS)PE (Subsegmental) pulmonary embolism 78 
SWITCO65+ Swiss cohort of elderly patients with venous thromboembolism 79 
VKA Vitamin K antagonist 80 
VTE Venous thromboembolism  81 
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INTRODUCTION 82 
Acute isolated subsegmental pulmonary embolism (SSPE), defined as 83 
pulmonary embolism (PE) that occurs in one or more subsegmental pulmonary artery 84 
branches but no larger order of vessels [1], is increasingly detected with the 85 
technological advance in computed tomography pulmonary angiography (CTPA) [2]. 86 
SSPE represents 7–36% of cases of PE [3-6], and the vast majority of patients with 87 
SSPE receive anticoagulant treatment [6]. However, the diagnosis and treatment of 88 
SSPE pose several challenges. Given a positive predictive value of as low as 25% for 89 
SSPE with CTPA and an only fair interobserver agreement between radiologists [7, 8], 90 
many cases of SSPE may represent false-positive results (e.g., artefacts) rather than 91 
true PE [9]. It has also been hypothesized that the lung may act as a natural filter to 92 
protect systemic circulation and therefore, SSPE may represent a normal finding [10]. 93 
Moreover, direct and indirect evidence from retro- and prospective studies suggests 94 
that SSPE may have a less severe clinical presentation and a lower risk of venous 95 
thromboembolism (VTE) recurrence and PE-related death than more proximal PE [3, 96 
4, 11], and that withholding anticoagulation in selected low-risk patients with SSPE 97 
(i.e., those without concomitant proximal deep vein thrombosis [DVT]) could be safe 98 
[4, 12, 13]. In contrast, another study found that patients with SSPE mimic those with 99 
more proximal PE in regard to their risk profile and clinical outcomes [5]. 100 
Although the majority of VTE cases occur in patients aged ≥65 years [14], little 101 
is known about the clinical presentation, VTE risk factors, processes of care, and 102 
outcomes in elderly patients with isolated SSPE. Previous studies on SSPE were 103 
mostly performed in patients aged <70 years [12], and whether their results can be 104 
generalized to the elderly remains unknown. To fill this gap of knowledge, we 105 
compared the clinical presentation, VTE risk factors, processes of care, and outcomes 106 
between elderly patients with isolated SSPE and those with more proximal PE. Given 107 
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the diagnostic uncertainty and doubtful clinical relevance of SSPE, we hypothesized 108 
that elderly patients with SSPE are less likely to experience adverse outcomes 109 
compared to patients with more proximal PE.  110 
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METHODS 111 
Cohort sample 112 
The study was conducted as part of the Swiss cohort of elderly patients with 113 
VTE (SWITCO65+) [15]. In this multicentre prospective cohort study, consecutive in- 114 
and outpatients aged ≥65 years with acute symptomatic, objectively confirmed VTE 115 
were enrolled at nine Swiss hospitals between September 2009 and March 2012 and 116 
followed until December 2013. Exclusion criteria comprised the inability to provide 117 
informed consent (i.e., severe dementia), impracticable follow-up due to terminal 118 
illness or place of living too far away from the study centre, insufficient German or 119 
French speaking ability, venous thromboses other than lower limb DVT or PE (e.g., 120 
catheter-related thrombosis), or prior enrolment in the cohort. The detailed study 121 
methods, including eligibility criteria, were published previously [15]. The study was 122 
approved by the ethics committees at each participating site. 123 
For the present study, we considered all patients from the original cohort who 124 
had an initial diagnosis of symptomatic PE (i.e., acute chest pain, new or worsening 125 
dyspnoea, or syncope) detected by an objective imaging exam, such as spiral CTPA, 126 
pulmonary angiography, or high-probability ventilation/perfusion scintigraphy [15]. 127 
Patients who had a diagnosis of SSPE without the presence of any more proximal PEs 128 
based on the interpretation of on-site radiologists were considered to have isolated 129 
SSPE. Because proximal DVT is associated with adverse outcomes in patients with 130 
PE [16], we excluded patients with isolated SSPE who had concomitant proximal DVT. 131 
 132 
Data collection 133 
For all enrolled patients, trained study nurses prospectively collected 134 
information about baseline demographics such as age, sex, localization of the index 135 
PE (SSPE vs. more proximal PE), VTE risk factors (active cancer, immobilisation, 136 
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major surgery, oestrogen therapy, and history of VTE), comorbidities (chronic heart 137 
failure, chronic lung disease, and history of major bleeding), clinical symptoms and 138 
signs of VTE (acute chest pain, new or worsening dyspnoea, new unilateral leg pain 139 
or leg swelling, pulse, systolic blood pressure, respiratory rate, body temperature, 140 
mental status, arterial oxygen saturation), and routine laboratory findings 141 
(haemoglobin, platelet count). The revised Geneva score as a clinical decision rule to 142 
assess the risk of PE in patients with suspected PE and the Pulmonary Embolism 143 
Severity Index (PESI) to estimate the 30-day overall mortality risk were calculated 144 
retrospectively [17, 18]. We further assessed the therapy initiated within one month of 145 
the index PE (vitamin K antagonists [VKA], parenteral anticoagulation, no 146 
anticoagulation, thrombolysis, inferior vena cava filter), concomitant treatments 147 
(antiplatelet and non-steroidal anti-inflammatory drugs), and the initial site of 148 
management (in- or outpatient setting). Type and duration of anticoagulation as well 149 
as the site of initial management was left to the discretion of the managing physicians. 150 
 151 
Study outcomes 152 
The primary outcome was the recurrence of symptomatic VTE during the follow-153 
up period, defined as a new or recurrent, fatal or non-fatal, symptomatic, and 154 
objectively confirmed PE and/or DVT, as previously described [15]. Secondary 155 
outcomes included overall mortality, PE-related mortality (defined as deaths certainly 156 
or possibly related to PE), and PE-specific quality of life based on the Pulmonary 157 
Embolism Quality of Life (PEmb-QoL) questionnaire. The PEmb-QoL questionnaire is 158 
an instrument with six dimensions (frequency of complaints, limitations in activities of 159 
daily living, work-related problems, social limitations, intensity of complaints, and 160 
emotional complaints) and 40 items to measure quality of life in patients with PE 161 
reflecting the patients’ perspective over the past four weeks [19, 20]. The summary 162 
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score ranges between zero (best quality of life) and 100 (worst quality of life) [21, 22] 163 
with an assumed minimal clinically important difference of 15 points [23]. We used the 164 
validated French and German versions of the PEmb-QoL [21, 22]. The tertiary outcome 165 
was the duration and quality of oral anticoagulation with VKAs, the latter expressed as 166 
the percentage of time spent in a given International Normalized Ratio [INR] range 167 
(<2.0, 2.0–3.0, >3.0) according to Rosendaal’s method [24]. Patients who did not take 168 
VKA, had less than two INR measurements, or died within the first six months, were 169 
excluded from analyses of anticoagulation. 170 
Follow-up included one telephone interview and two face-to-face evaluations 171 
during the first year of study participation and then semi-annual contacts, alternating 172 
between face-to-face evaluations and telephone calls, as well as periodic hospital chart 173 
reviews. As part of the follow-up interviews/visits, study nurses obtained information 174 
about the date and localization of VTE recurrence, death, and PE-specific quality of 175 
life. We also collected INR values throughout follow-up. A committee of 3 independent, 176 
blinded clinical experts adjudicated all outcomes. They classified the cause of all 177 
deaths as definitely due to PE (i.e., confirmed by autopsy or death following a clinically 178 
severe PE), possibly related to PE (i.e., death in a patient who died suddenly without 179 
any other explanation), or due to another cause. PE-related death was defined as 180 
death definitely or possibly related to recurrent PE. Final assignments were based on 181 
the full consensus of this committee. 182 
 183 
Statistical analyses 184 
We compared baseline characteristics, mean PEmb-QoL summary scores at 185 
three months, duration of anticoagulation, and the percentage of time spent in a given 186 
INR range (<2.0, 2.0–3.0, >3.0) between patients with isolated SSPE and those with 187 
more proximal PE using chi-square or Wilcoxon rank-sum tests as appropriate. A P-188 
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value <0.05 was considered statistically significant. Recurrent VTE, overall mortality, 189 
and PE-related mortality in patients with SSPE vs. those with more proximal PE were 190 
compared at three months and over the entire follow-up period. We additionally 191 
compared PE-related deaths that occurred during the index hospitalization to assess 192 
mortality due to the index PE. The 3-year cumulative incidences of recurrent VTE 193 
events by localization of PE were compared using the Aalen-Johansen estimator and 194 
the Gray test, which both account for the competing risk of death [25, 26]. For mortality, 195 
we used the Kaplan-Meier estimator and the log-rank test. 196 
We explored the associations between SSPE and the time to a first recurrent 197 
VTE using competing risk regression [27], accounting for non-PE-related death as a 198 
competing event. The method yields sub-hazard ratios (SHR) with corresponding 95% 199 
confidence intervals (CIs). We adjusted the models for risk factors previously shown to 200 
be associated with recurrent VTE (age, sex, active cancer, history of VTE) [28-32], as 201 
well as periods of anticoagulation as a time-varying covariate. For overall mortality, we 202 
used Cox-regression with robust standard errors, adjusting for age, sex, active cancer, 203 
chronic lung disease, heart failure [18, 33, 34], and periods of anticoagulation as a 204 
time-varying covariate. Because the diagnosis of SSPE based on ventilation/perfusion 205 
scanning is not standardized, we excluded all non-CTPA-based PE cases in a 206 
sensitivity analysis. We assumed missing values in adjustment variables to be normal 207 
or absent as done previously [18, 35]. All analyses were done using Stata 15 (Stata 208 
Corporation, College Station, Texas).  209 
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RESULTS 210 
Study sample 211 
Of 1863 screened patients with symptomatic VTE, we excluded 462 who had 212 
≥1 exclusion criterion and 398 who did not consent to participate (Fig. 1). After the 213 
exclusion of another 425 patients who withdrew from the study within one day of 214 
enrolment, refused the use of their data, had objectively confirmed DVT only, or had 215 
concomitant proximal DVT, our final sample comprised 578 patients. Of these, 64 had 216 
isolated SSPE (11%) and 514 more proximal PE. 217 
The median age was 75 years (interquartile range [IQR] 70–81 years) and 53% 218 
of patients were men. Patients with isolated SSPE were more likely to have active 219 
cancer (28% vs. 15%, P=0.01) and less often to have a pulse ≥110/min. (3% vs. 13%, 220 
P=0.02) than patients with proximal PE (Table 1). The revised Geneva score, cardiac 221 
biomarker levels, and the short-term mortality risk based on the PESI were comparable 222 
between the two groups. 223 
All but four patients (1 with isolated SSPE, 3 with more proximal PE) were 224 
treated with initial anticoagulants (VKA or parenteral anticoagulation), but the initiation 225 
of VKA therapy was less frequent in patients with isolated SSPE than in patients with 226 
more proximal PE (80% vs. 91%, P=0.01; Table 1). Patients with isolated SSPE were 227 
more often treated as outpatients (11% vs. 4%, P=0.02). The median follow-up period 228 
was 30 months (IQR 18–36 months). 229 
 230 
Primary outcome (recurrence of VTE) 231 
The risk of recurrent VTE at three months and over the entire follow-up period 232 
(Table 2), and the 3-year cumulative incidence of recurrent VTE (Fig. 2a) did not differ 233 
significantly between patients with SSPE and those with more proximal PE. After 234 
adjustment, there was no statistically significant difference in recurrent VTE during 235 
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follow-up between the two groups (SHR 0.64, 95%CI: 0.25–1.62; Table 3). Excluding 236 
the 58 patients in whom PE-diagnosis was not based on CTPA in a sensitivity analysis 237 
did not substantially change the results (SHR 0.57, 95%CI: 0.20–1.62; Table 3). 238 
 239 
Secondary outcomes (overall mortality, PE-related mortality, PE-specific 240 
quality of life) 241 
Of the 18 patients with isolated SSPE who died during follow-up, two died from 242 
possible recurrent PE (sudden death without any other explanation) on day 82 and 243 
1120 of follow-up. Of the 97 patients with proximal PE who died during follow-up, 21 244 
patients died from definite (n=6) or possible PE (n=15). Of these, seven died from PE 245 
during the hospitalization for index PE. Overall mortality and mortality definitely or 246 
possibly related to PE during the index hospitalization, at three months, and over the 247 
entire follow-up period (Table 2), as well as the 3-year cumulative incidence of overall 248 
mortality (Fig. 2b), did not differ significantly between patients with isolated SSPE and 249 
those with more proximal PE. After adjustment, the risk of overall mortality did not differ 250 
between the two groups (hazard ratio [HR] 1.12, 95%CI: 0.64–1.96; Table 3). After the 251 
exclusion of the 58 patients without a CTPA-based PE diagnosis, mortality did not differ 252 
by PE localization (HR 1.34, 95%CI: 0.71–2.53, Table 3). 253 
PE-specific quality of life, expressed as the PEmb-QoL summary score at three 254 
months following the index PE, was similar in patients with isolated SSPE and those 255 
with more proximal PE (median 22.8 vs. 22.9 points; P=0.70). 256 
 257 
Tertiary outcomes (duration and quality of anticoagulation) 258 
The median duration of initial anticoagulation did not differ between patients with 259 
SSPE and those with more proximal PE (10.7 [IQR 6.1–24.1] vs. 12.3 [6.3–28.7] 260 
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months; P=0.34; Table 4). The quality of anticoagulation, expressed as the time in a 261 
given INR range, was also comparable between the PE groups (Table 5).  262 
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DISCUSSION 263 
In our prospective study of elderly patients with acute symptomatic PE, patients 264 
with isolated SSPE did not differ significantly in their clinical presentation, but had a 265 
higher prevalence of cancer, and a higher probability of receiving outpatient treatment 266 
than patients with more proximal PE. The PESI risk classes, the duration and quality 267 
of anticoagulation, and short- and long-term clinical outcomes did not differ significantly 268 
between the two groups, although the power to detect differences might have been 269 
limited given the small number of events. To our knowledge, this is the first study 270 
exploring differences between SSPE and proximal PE in the elderly. 271 
Whether isolated SSPE is clinically more benign than more proximal PE remains 272 
controversial. Studies of younger patients demonstrated that patients with isolated 273 
SSPE have a lower prevalence of new/worsening dyspnoea and concomitant DVT [3, 274 
36], lower levels of biomarkers, fewer signs of right-ventricular dysfunction [3], and a 275 
lower prevalence of arterial hypoxemia and tachycardia than patients with more 276 
proximal PE [3, 37]. Our results could not show that elderly patients with isolated SSPE 277 
have a more subtle clinical presentation. 278 
Elderly patients with isolated SSPE and more proximal PE did not differ in terms 279 
of VTE risk factors and comorbid conditions in our study, with the exception of a higher 280 
cancer prevalence in the SSPE group (28% vs. 15%). The latter may be potentially 281 
explained by a lower threshold to perform CTPA in elderly patients with active cancer, 282 
thus increasing the rate of detected oligosymptomatic SSPE. Alternatively, the 283 
prothrombotic state associated with cancer could result in a greater risk for small, 284 
peripheral PE in the elderly. 285 
Our finding that the vast majority of patients with isolated SSPE are managed 286 
with anticoagulation treatment is consistent with the results from surveys and other 287 
studies [6, 38, 39]. We did not observe a statistically significant difference in the 288 
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duration of initial anticoagulation in patients with SSPE and more proximal PE, 289 
demonstrating that physicians do not primarily use the localization of PE to determine 290 
the duration of anticoagulant treatment. The higher proportion of outpatient 291 
management in patients with SSPE compared with proximal PE (11% vs. 4%) indicates 292 
that physicians perceive the risk of adverse outcomes related to SSPE to be lower. 293 
The lower proportion of VKA treatment in patients with SSPE is most probably 294 
attributable to the higher prevalence of cancer in this group. 295 
We did not find statistically significant differences in recurrent VTE, overall 296 
mortality, PE-related mortality, and PE-specific quality of life between patients with 297 
isolated SSPE and proximal PE, acknowledging that the number of outcome events 298 
was low in our study. The slightly higher 3-year cumulative mortality incidence in 299 
patients with SSPE (29% vs. 20%) could be explained with the higher prevalence of 300 
cancer in this group. After adjustment for potential confounders, isolated SSPE was 301 
not independently associated with a lower risk of clinical outcomes compared to 302 
proximal PE. Our results are consistent with a study by den Exter, et al., who did not 303 
find statistically significant differences in the 3-month risks of recurrent VTE and overall 304 
mortality between anticoagulated patients with isolated SSPE and more proximal PE, 305 
although the age of their study population was lower (mean age 56 years) [5]. However, 306 
as almost all patients received anticoagulation in our and den Exter’s study, outcome 307 
comparisons between SSPE vs. proximal PE may be blurred. Interestingly, seven 308 
deaths were related to the index PE in the proximal PE group vs. zero in the SSPE 309 
group. This finding indicates that case-fatality may not be a direct consequence of 310 
SSPE, which is unlikely to cause hemodynamic instability. 311 
A growing body of evidence from retrospective and non-randomized prospective 312 
studies suggests that withholding anticoagulation may be as safe as anticoagulant 313 
treatment in selected low-risk patients with isolated SSPE [12, 13]. Our study does not 314 
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provide any evidence that isolated SSPE represents a clinically more benign form of 315 
PE in the elderly. However, a substantial proportion of patients in our sample had 316 
cancer (28%) or concomitant DVT (3%), two well-known risk factors for recurrent VTE 317 
[28, 31, 32], and death [16, 18, 33, 34]. Thus, withholding anticoagulation in selected 318 
low-risk patients with isolated SSPE, i.e., those without cancer or concomitant DVT, 319 
may still be an option but the risk-benefit ratio of such an approach should be examined 320 
in a randomized trial before it can be adopted into clinical practice. 321 
Our study has potential limitations. First, as patients were solely enrolled in 322 
hospital in- and outpatient services, healthier patients with clinically more benign forms 323 
of SSPE who were diagnosed and entirely managed outside the hospital may be 324 
underrepresented in our study. Second, as in most studies of SSPE, the diagnosis of 325 
isolated SSPE was made by on-site radiologists and was not independently 326 
adjudicated [5, 40, 41]. Because the interobserver agreement for SSPE based on 327 
CTPA is only fair (k=0.38) [8] and the diagnosis of SSPE based on ventilation/perfusion 328 
scanning is not standardized [42], we cannot exclude the possibility that some patients 329 
were misclassified as having isolated SSPE in our study. However, when we 330 
considered only CTPA-based PEs in a sensitivity analysis, the results did not change 331 
markedly, confirming the robustness of our findings. Third, we could not distinguish 332 
isolated single from multiple SSPEs, as the number of SSPEs were not documented 333 
in our database. As no studies comparing the prognosis of single vs. multiple isolated 334 
SSPEs exist, whether patients with single vs. multiple SSPE have differential 335 
outcomes, is unknown. Fourth, the assessment of concomitant DVT was not 336 
systematic but was left to the discretion of the managing physicians, which must have 337 
resulted in an underestimation of the true prevalence of concomitant DVT. Fifth, this 338 
study is an ancillary study from the SWITCO65+ cohort and we have not done a power 339 
calculation. Thus, the relatively small number of events limits the power to detect 340 
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potential outcome differences between SSPE and more proximal PE. Finally, direct 341 
oral anticoagulants (DOACs) were not authorized for treatment of acute VTE during 342 
the study recruitment period in Switzerland and it is possible that bleeding rates would 343 
be lower if DOACs rather than VKAs had been used [43]. 344 
In conclusion, clinical presentations and incidences of adverse outcomes did 345 
not differ significantly between elderly patients with SSPE and those with proximal PE, 346 
although the power to detect differences might have been limited given the small 347 
number of events. Overall, our study does not provide any evidence that unselected, 348 
elderly patients with isolated SSPE have a benign clinical course and may not need 349 
anticoagulant treatment. Whether withholding anticoagulation in selected low-risk 350 
patients with isolated SSPE (e.g., those without cancer or concomitant DVT) is safe, 351 
must be examined in a future randomized-controlled trial. 352 
353 
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FIGURE LEGENDS 519 
Figure 1. 520 
Patient flow chart. 521 
 522 
Figure 2. 523 
a. Aalen-Johansen estimates of recurrent VTE by localization of PE 524 
The 3-year cumulative incidence of recurrent VTE was 7% in patients with isolated 525 
SSPE and 12% in patients with more proximal PE (P=0.413 by the Gray-test). 526 
 527 
b. Kaplan-Meier estimates of overall mortality by localization of PE 528 
The 3-year cumulative incidence of overall mortality was 29% in patients with isolated 529 
SSPE and 20% in patients with more proximal PE (P=0.086 by the log-rank test). 530 
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Table 1. Patient baseline characteristics and treatments by localization of PE 
 
All 
(N=578) 
Isolated 
SSPE (N=64) 
Proximal PE 
(N=514) 
 
Characteristicsa n (%) or median (interquartile range) P-value 
Baseline characteristics     
Patient age, years 75 (70; 81) 76 (69; 81) 74 (70; 81) 0.85 
Male sex 308 (53) 27 (42) 281 (55) 0.06 
VTE risk factors     
  Active cancerb 94 (16) 18 (28) 76 (15) 0.01 
  Immobilisationc 127 (22) 11 (17) 116 (23) 0.33 
  Major surgeryd 91 (16) 11 (17) 80 (16) 0.74 
  Current oestrogen therapye 19 (3) 4 (6) 15 (3) 0.16 
  History of VTE 155 (27) 15 (23) 140 (27) 0.52 
Comorbid conditions     
  Chronic heart failure 42 (7) 5 (8) 37 (7) 0.86 
  Chronic lung disease 93 (16) 14 (22) 79 (15) 0.18 
  History of major bleedingf 64 (11) 6 (9) 58 (11) 0.68 
Clinical symptoms & signs of VTE     
  Acute chest paing 280 (48) 35 (55) 245 (48) 0.29 
  New or worsening dyspnoeag 472 (82) 47 (73) 425 (83) 0.07 
  New unilateral leg pain or swellingg 129 (22) 17 (27) 112 (22) 0.39 
  Confirmed distal DVTh 28 (5) 2 (3) 26 (5) 0.50 
  Pulse ≥110/min. 71 (12) 2 (3) 69 (13) 0.02 
  Systolic BP <100 mm Hg 22 (4) 2 (3) 20 (4) 0.81 
  Respiratory rate ≥30/min. 20 (3) 0 (0) 20 (4) 0.12 
  Body temperature <36°C 43 (7) 4 (6) 39 (8) 0.75 
  Altered mental statusi 20 (3) 0 (0) 20 (4) 0.11 
  Arterial O2 saturation <90% 89 (15) 6 (9) 83 (16) 0.20 
     (continued) 
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All 
(N=578) 
Isolated 
SSPE (N=64) 
Proximal PE 
(N=514) 
 
Characteristics n (%) or median (interquartile range) P-value 
Clinical probability for PE [17]    0.54 
  Low 98 (17) 9 (14) 89 (17) - 
  Intermediate 427 (74) 47 (73) 380 (74) - 
  High 53 (9) 8 (13) 45 (9) - 
PESI risk classes [18]    0.51 
  I 4 (1) 1 (2) 3 (1) - 
  II 192 (33) 22 (34) 170 (33) - 
  III 177 (31) 18 (28) 159 (31) - 
  IV 131 (23) 18 (28) 113 (22) - 
  V 74 (13) 5 (8) 69 (13) - 
Diagnostic method    <0.001 
  Positive spiral CT 520 (90) 47 (73) 473 (92) - 
  Pulmonary angiography 2 (0) 1 (2) 1 (0) - 
  High-probability ventilation/perfusion 
  lung scintigraphy 
56 (10) 16 (25) 40 (8) - 
Laboratory findings     
  Hs-cTNT, pg/mL 15 (8; 32) 15 (6; 28) 15 (8; 33) 0.57 
  NT-proBNP, pg/mL 571 
(209; 1566) 
547 
(272; 1386) 
577 
(205; 1644) 
0.95 
  D-dimer, ng/mL 2341  
(1505; 3560) 
2005 
(1087; 3651) 
2361 
(1531; 3545) 
0.09 
  Anemiaj 221 (38) 28 (44) 193 (38) 0.23 
  Thrombocytopeniak 83 (14) 6 (9) 77 (15) 0.26 
VTE-related treatment     
Type of AC started within 1 month of PE     
  VKA therapyl 518 (90) 51 (80) 467 (91) 0.01 
  Parenteral ACm 564 (98) 61 (95) 503 (98) 0.21 
(continued) 
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All 
(N=578) 
Isolated 
SSPE (N=64) 
Proximal PE 
(N=514) 
 
Characteristics n (%) or median (interquartile range) P-value 
  No initial AC 4 (1) 1 (2) 3 (1) 0.37 
  Thrombolysisn 19 (3) 0 (0) 19 (4) 0.12 
  Inferior vena cava filter 8 (1)       0 (0)       8 (2)       0.32 
Concomitant treatments     
  Antiplatelet drugs/NSAIDso 237 (41) 29 (45) 208 (40) 0.46 
Outpatient managementp 28 (5) 7 (11) 21 (4) 0.02 
 
Abbreviations: (SS)PE= (subsegmental) pulmonary embolism; VTE= venous thromboembolism; DVT= 
deep vein thrombosis; BP= blood pressure; CT= computed tomography; Hs-cTNT= high-sensitivity 
cardiac troponin T; VKA= vitamin K antagonists; AC= anticoagulation; NSAID= non-steroidal anti-
inflammatory drugs. 
aData were missing for pulse (1%), systolic BP (1%), respiratory rate (22%), body temperature (2%), 
arterial O2 saturation (6%), Hs-cTNT (13%), NT-proBNP (13%), D-dimer (15%), anemia (2%), and 
thrombocytopenia (2%). 
bSolid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, or palliative care during 
the last 3 months. 
cBed rest >72 hours, voyage in sitting position for >6 hours, fracture or cast of the lower extremity during 
the last 3 months. 
dSurgery requiring general or spinal anaesthesia during the last 3 months. 
eAny oestrogen-containing treatment such as osteoporosis prevention/treatment, oral hormone 
replacement therapy, or antitumor treatment for breast or prostate cancer during the last 3 months. 
fHistory of a symptomatic bleeding in a critical area or organ and/or bleeding causing a fall in 
haemoglobin level of ≥20 g/L, or leading to transfusion of ≥2 units of whole blood or red cells [44]. 
gDuring the last 21 days. 
hConfirmed by compression ultrasonography or contrast venography. 
iDisorientation, lethargy, stupor, or coma. 
jHaemoglobin <13 g/dL in men or <12 g/dL in women. 
kPlatelet count <150 G/L. 
lAcenocoumarol or phenprocoumon. 
mIntravenous or subcutaneous unfractionated heparin, dalteparin, enoxaparin, nadroparin, 
fondaparinux, or other. 
nSystemic or catheter-directed thrombolysis. 
oAspirin, clopidogrel, prasugrel, aspirin/dipyridamol, or any NSAID (e.g., ibuprofen). 
pHospital stay for <24 hours. 
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Table 2. Clinical outcomes by localization of PE 
 
Abbreviations: (SS)PE= (subsegmental) pulmonary embolism; VTE= venous thromboembolism; DVT= 
deep vein thrombosis. 
aCause of death was adjudicated as possibly related to PE. 
bCause of death was adjudicated as definitely due to PE in 3 patients and as possibly related to PE in 7 
patients. 
cCause of death was adjudicated as possibly related to PE in both patients. 
dCause of death was adjudicated as definitely due to PE in 6 patients and as possibly related to PE in 
15 patients. 
 
  
  
All 
(N=578) 
Isolated SSPE 
(N=64) 
Proximal PE 
(N=514) 
 
Clinical outcomes n (%) P-value 
Recurrent VTE     
  At 3 months 7 (1) 1 (2) 6 (1) 0.56  
  Entire follow-up period 59 (10) 5 (8) 54 (11) 0.66  
Recurrent PE     
  At 3 months 6 (1) 1 (2) 5 (1) 0.51 
  Entire follow-up period 45 (8) 3 (5) 42 (8) 0.46  
Recurrent DVT     
  At 3 months 1 (0) 0 (0) 1 (0) 1.00 
  Entire follow-up period 17 (3) 2 (3) 15 (3) 1.00 
Overall mortality     
  At 3 months 31 (5) 7 (11) 24 (5) 0.07  
  Entire follow-up period 115 (20) 18 (28) 97 (19) 0.10  
Definite or possible PE-related death     
  During the index hospitalization 7 (1) 0 (0) 7 (1) 1.00 
  At 3 months 11 (2) 1 (2)a 10 (2)b 1.00  
  Entire follow-up period 23 (4) 2 (3)c 21 (4)d 0.52  
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Table 3. Association between localization of PE and VTE recurrence or overall 
mortality 
 
All PE diagnosis 
(N=578) 
CTPA-based PE diagnosis only 
(N=520) 
 Adjusted sub-hazard ratio (95%CI) 
VTE recurrence   
  Proximal PE Reference Reference 
  Isolated SSPE 0.64 (0.25–1.62)a 0.57 (0.20–1.62)a 
 Adjusted hazard ratio (95%CI) 
Overall mortality   
  Proximal PE Reference Reference 
  Isolated SSPE 1.12 (0.64–1.96)c 1.34 (0.71–2.53)c 
 
Abbreviations: (SS)PE= (subsegmental) pulmonary embolism; CTPA= computed tomography 
pulmonary angiography; CI= confidence interval; VTE= venous thromboembolism. 
aAdjusted for age, sex, active cancer, prior VTE, and periods of anticoagulation as a time-varying 
covariate. 
bAdjusted for age, sex, previous major bleeding, active cancer, low physical activity, anemia, 
thrombocytopenia, antiplatelet or non-steroidal anti-inflammatory drugs, and periods of anticoagulation 
as a time-varying covariate.  
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Table 4. Duration of anticoagulation by localization of PE 
  
All  
(N=527)a 
Isolated SSPE 
(N=56) 
Proximal PE 
(N=471) 
 
 n (%) or median (interquartile range) P-value 
Duration of initial AC, months 12.2 (6.2; 28.0) 10.7 (6.1; 24.1) 12.3 (6.3; 28.7) 0.34 
Duration of initial AC    0.35 
≤3 months 38 (7) 7 (13) 31 (7) - 
3–6 months 74 (14) 6 (11) 68 (14) - 
6–12 months 147 (28) 17 (30) 130 (28) - 
>12 months 268 (51) 26 (46) 242 (51) - 
 
Abbreviations: (SS)PE= (subsegmental) pulmonary embolism; AC= anticoagulation. 
aPatients who died within the first 6 months were excluded from this analysis (N=51).  
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Table 5. Quality of oral anticoagulant by localization of PE 
INR rangea 
 
All  
(N=494) 
Isolated SSPE 
(N=48) 
Proximal PE 
(N=446) 
 
  median % of time (interquartile range) P-value 
2.0–3.0 65.1 (48.1; 80.5) 66.4 (45.3; 82.2) 65.0 (48.1; 80.5) 0.71 
>3.0 10.4 (3.1; 20.5) 11.4 (3.2; 20.3) 10.3 (3.1; 20.6) 0.91 
<2.0 15.7 (6.3; 33.3) 15.5 (3.9; 30.6) 15.7 (6.6; 33.5) 0.55 
 
Abbreviations: (SS)PE= (subsegmental) pulmonary embolism; INR= international normalized ratio.  
aOnly patients with initial vitamin K antagonist treatment and at least two INR measurements were 
considered. 
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Figure 1. 
  
Screened (N=1863) 
Enrolled (N=1003) 
Patients not eligible (N=462)  
Venous thromboses other than lower limb DVT or PE  
(e.g., catheter-related thrombosis) (N=28)  
Insufficiency spoken ability in German or French (N=51)  
Inability to provide informed consent (N=285)  
Follow-up not possible (N=192) 
Patients who 
did not consent 
(N=398) 
Excluded from analysis (N=425) 
Patients who withdrew consent and did not allow 
the use of their data (N=12) 
Deep venous thromboembolism only (N=304) 
Patients with concomitant proximal DVT (N=109) 
Analyzed (N=578) 
Patients with more 
proximal pulmonary 
embolism (N=514) 
Patients with isolated 
subsegmental pulmonary 
embolism (N=64) 
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